Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 3/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | STAT6 | P42226 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL2505730 | 1.00 | ADK (0.40) | ADKSLC29A1HSPA8HSPA5HIF1A | |
| Adenine SCHEMBL14636444 | 0.85 | HIF1A (0.49) | ADKSLC29A1HSPA8HSPA5HIF1A | |
| 6-Chloroguanine SCHEMBL10674719 | 0.84 | LMNA (0.40) | SLC29A1HIF1ASTAT6SMN1; SMN2MEN1 | |
| Ribose (Furanose) SCHEMBL2497745 | 0.83 | LMNA (0.49) | HIF1ASTAT6SMN1; SMN2MEN1ADORA3 | |
| Adenine SCHEMBL9007542 | 0.80 | FBP1 (0.46) | ADKSLC29A1HSPA8HSPA5HIF1A | |
| Ribose (Furanose) SCHEMBL8605925 | 0.79 | ADK (0.40) | ADKSLC29A1HIF1ASTAT6SMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL17824409 | 0.79 | ADK (0.40) | ADKSLC29A1HIF1ASTAT6SMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL4542672 | 0.79 | ADK (0.40) | ADKSLC29A1HIF1ASTAT6SMN1; SMN2 | |
| SCHEMBL7764674 | 0.77 | ADK (0.54) | ADKTSHR | |
| SCHEMBL9081 | 0.76 | CHEK1 (0.42) | SMN1; SMN2DPP4MEN1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301348-B2 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | ACADEMIA SINICA (TW) | 2019-05-28 | — | — | US | claimed |
| CN-106414456-B | Compounds for the prevention and treatment of neurodegenerative diseases and pain | 中央研究院 | 2018-12-14 | — | — | CN | claimed |
| EP-3060566-B1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2018-09-05 | — | — | EP | claimed |
| CN-106414456-A | Compounds for the prevention and treatment of neurodegenerative diseases and pain | 中央研究院 | 2017-02-15 | — | — | CN | claimed |
| US-20160264613-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2016-09-15 | — | — | US | claimed |
| EP-3060566-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | Academia Sinica (TW) | 2016-08-31 | — | — | EP | claimed |
| WO-2015061426-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2015-04-30 | — | — | WO | claimed |
| US-7297787-B2 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | GLAXO GROUP LIMITED (GB) | 2007-11-20 | — | — | US | claimed |
| EP-1370569-B1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LTD (GB) | 2005-08-31 | — | — | EP | claimed |
| US-20050176949-A1 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | claimed |
| EP-1370569-A1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074781-A1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | claimed |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (TW) | 2019-07-09 | — | — | US | disclosed |
| US-10301348-B2 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | ACADEMIA SINICA (TW) | 2019-05-28 | — | — | US | disclosed |
| CN-106414456-B | Compounds for the prevention and treatment of neurodegenerative diseases and pain | 中央研究院 | 2018-12-14 | — | — | CN | disclosed |
| EP-3060566-B1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2018-09-05 | — | — | EP | disclosed |
| EP-1370569-B1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LTD (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176949-A1 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1370569-A1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074781-A1 | PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264613-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ADORA2A, ADORA3, ADORA2B | ADK 23/4885SLC29A1 340/4885HSPA8 2418/4885 |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | ADK 18/4885SLC29A1 6/4885HSPA8 2058/4885 |
| US-20050176949-A1 | Process for preparing N6 substituted aminopurine ribofuranose nucleosides | ADORA3, NUDT1, ADORA1 | ADK 69/4885SLC29A1 24/4885HSPA8 2709/4885 |
| US-10301348-B2 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | ADORA2A, ADORA3, ADORA2B | ADK 23/4885SLC29A1 340/4885HSPA8 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.